- |||||||||| 6 Mercaptopurine / Teva
[VIRTUAL] METHOTREXATE FOR THE INDUCTION OF REMISSION IN ULCERATIVE COLITIS () - Mar 25, 2021 - Abstract #CDDW2021CDDW_270; Methotrexate demonstrated no benefit over placebo or active comparators for the induction of steroid-free remission. Future research is ongoing to explore the utility of combination therapy with monoclonal antibody biologic therapy for the treatment of active ulcerative colitis.
- |||||||||| methotrexate / Generic mfg., cyclosporine / Generic mfg.
Biomarker, Review, Journal: Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. (Pubmed Central) - Feb 26, 2021 Facing these issues, personalized medicine in IBD may benefit from a combined approach, made by TDM protocols and pharmacogenetic analyses in a timeline that necessarily considers the frailty of patients, the chronic administration of drugs, and the possible worsening of the disease. Therefore, the present review presents and discusses the activities of TDM protocols using mABs in light of the most recent results, with special attention on the integration of other actions aimed at exploiting the most effective and safe therapeutic effects of drugs prescribed in IBD patients.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J
Journal: Kayexalate-induced colitis and rectal stricture. (Pubmed Central) - Feb 23, 2021 This was treated with a fully covered metal stent for 12 weeks with only partial improvement of the stricture. He was hence referred for ultra-low anterior resection of rectum and take down of colostomy.
- |||||||||| 6 Mercaptopurine / Teva
Clinical, Journal: Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with NUDT15 heterozygosity. (Pubmed Central) - Jan 22, 2021 The median maintenance dosage of 6-mercaptopurine was 0.25 mg/kg/day (range, 0.19-0.36 mg/kg/day), and 6-thioguanine nucleotides level was 230 (104-298) pmol/8 × 108 red blood cells...Cumulative non-relapse rates in the patients with UC treated with thiopurine monotherapy and surgery-free rates in CD patients treated with combination therapy (thiopurines and anti-tumor necrosis factor-α agents) for maintenance remission were not significantly different at 60 months (C/C vs. C/T, P= 0.339 and P= 0.422, respectively). Low-dose thiopurine treatment is an effective and acceptable treatment for patients with C/T genotype.
- |||||||||| 6 Mercaptopurine / Teva
Journal: Nur77 promotes embryo adhesion by transcriptionally regulating HOXA10 expression. (Pubmed Central) - Jan 6, 2021 Nur77 and 6-MP may provide a basis to develop a new treatment for patients who suffer from embryo adhesion dysfunction. Abbreviations: HB-EGF: heparin-binding epidermal growth factor-like growth factor; HOXA10: homeobox A10; NGFI-B: nerve growth factor-induced gene B; RIF: recurrent implantation failure; RPL: recurrent pregnancy loss; 6-MP: 6-mercaptopurine; IGFBP-1: insulin-like growth factor binding protein-1; LIF: leukemia inhibitory factor; IL-1β: Interleukin - 1β; CRISPR/Cas9: Clustered Regularly Interspaced Short Palindromic Repeats; AF-1: activation function-1 domain; HIF-1α: hypoxia-inducible factor 1α; CREB: cAMP response element binding.
- |||||||||| 6 Mercaptopurine / Teva
Journal: Full Potential of 6-Mercaptopurine in IBD May Remain Untapped. (Pubmed Central) - Jan 5, 2021 The different biological behavior of this case underscores the need for studies on a larger number of cases to explore the significance of the aforementioned coexistent features. No abstract available
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda
[VIRTUAL] Left Orbital Myositis in a Patient with Crohn’s Disease in Remission with Vedolizumab () - Dec 18, 2020 - Abstract #AIBD2020AIBD_204; Anti-TNF agents were not chosen since the patient had a history of primary non-response to infliximab...Although there is limited data for the newer biologic therapies, anti-TNF agents have been historically used with success. An individualized approach to treatment is necessary, with consideration of prior biologic exposure as well as adverse effects.
- |||||||||| 6 Mercaptopurine / Teva
Journal: The critical size of gold nanoparticles for overcoming P-gp mediated multidrug resistance. (Pubmed Central) - Dec 18, 2020 Based on the three-dimensional structural characteristics of P-gp, gold nanoparticles (AuNPs) with average sizes of 4.1 nm and 5.4 nm were designed for the construction of nanodrug delivery systems (NanoDDSs), with the anticancer molecules 2-(9-anthracenylmethylene)-hydrazinecarbothioamide (ANS) and 6-mercaptopurine (6-MP) modified on the AuNP surfaces through the thiol group...Verapamil and P-gp antibody competitive experiments, combined with the cellular uptake of AuNPs, indicated that larger NanoDDSs were more conducive to intracellular drug accumulation and thus had improved anticancer activities, due to a size mismatch between the nanoparticles and the active site of P-gp, and, therefore, reduced drug efflux was seen...Therefore, the critical size of AuNPs for overcoming MDR was identified to be between 4.1 nm and 5.4 nm. This provides a more accurate description of the composite dimension requirements for NanoDDSs that are designed to overcome MDR.
- |||||||||| methotrexate / Generic mfg.
Clinical, Journal: Gastrointestinal lesion in adult-onset Langerhans cell histiocytosis. (Pubmed Central) - Dec 16, 2020 Although gastrointestinal LCH lesions are rare, they were more common than expected in our cases of multisystem LCH. However, these lesions were relatively small and did not affect the patients' clinical courses.
- |||||||||| 6 Mercaptopurine / Teva
[VIRTUAL] LANGERHANS CELL HISTIOCYTOSIS AS A SINGLE INJURY IN HARD PALATE () - Nov 26, 2020 - Abstract #HEMO2020HEMO_322; It was the treatment chosen for the patient in the case, 2 courses of Prednisone 1 mg / kg / day for 4 weeks with an interval of 2 weeks, Vinblastine 6 mg / m2 once a week for 6 weeks with an interval of 21 days between courses, followed by maintenance with 6-mercaptopurine 30 mg / m2 (max: 50 mg / day), prednisone 1 mg / kg D1 at D5, Vinblastine 6 mg / m2 at D1 every 21 days until completing 52 weeks from the start of treatment. LCH can be reactivated and lead to chronic local symptoms or induce organ dysfunction.
- |||||||||| 6 Mercaptopurine / Teva
[VIRTUAL] ACUTE MYELOID LEUKEMIA: EVOLUTION OF CASE WITH SUCCESSIVE ISCHEMIC BRAIN VASCULAR ACCIDENTS () - Nov 26, 2020 - Abstract #HEMO2020HEMO_275; With this diagnosis, chemotherapy continued with all-trans retinoic acid (ATRA ), methotrexate and mercaptopurine, going into remission three months after the start of treatment, with no need for bone marrow transplantation...The treatment is divided into 3 phases: Induction, which aims to reduce the number of leukemic cells, the most suitable drug being trans-retinoic acid (ATRA) combined with arsenic trioxide (ATO) or chemotherapy with anthracycline or anthracycline chemotherapy more ACT... Early diagnosis and treatment are essential for the successful treatment of AML subtype M3, in addition to preventing future ischemic events, which are influenced by increased blood viscosity due to the presence of blasts in peripheral blood.
- |||||||||| dexamethasone / Generic mfg.
[VIRTUAL] ALL-TRANS RETINOIC ACID-INDUCED MYOSITIS IN A 36-YEAR-OLD PATIENT WITH ACUTE PROMYELOCYTIC LEUKAEMIA () - Nov 26, 2020 - Abstract #HEMO2020HEMO_233; He was treated with ATRA withdrawal and dexamethasone with rapid improvement of his condition...At the time of this writing he is receiving maintenance with 6-mercaptopurine, methotrexate and ATRA...To the best of our knowledge, only 15 cases of ATRA-related myositis have been reported to date. This report highlights the importance of a rare but important ATRA side effect that, if not promptly recognized, can have a fatal course.
- |||||||||| citalopram / Generic mfg., telmisartan / Generic mfg.
Clinical, Journal: Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). (Pubmed Central) - Nov 6, 2020 P3 Exclusion criteria are: Inability to make an informed decision to participate (e.g.: dementia, guardianship); Rockwood Clinical Frailty Scale ≥7; Long QT syndrome; QTc interval > 500 ms; Heart rate 5.5 mmol/L or <3.5 mmol/L; Ongoing treatment with piperaquine, halofantrine, dasatinib, nilotinib, hydroxyzine, domperidone, citalopram, escitalopram, potent inhibitors or inducers of cytochrome P450 CYP3A4 isoenzyme, repaglinide, azathioprine, 6-mercaptopurine, theophylline, pyrazinamide, warfarin; Known hypersensitivity to any of the trial drugs or to chloroquine and other 4-aminoquinolines, amodiaquine, mefloquine, glafenine, floctafenine, antrafenine, ARB; Hepatic porphyria; Liver failure (Child-Pugh stage ≥B); Stage 4 or 5 chronic kidney disease (GFR <30 mL/min/1.73 m²); Dialysis; Hypersentivity to lactose; Lactase deficiency; Abnormalities in galactose metabolism; Malabsorption syndrome; Glucose-6-phosphate dehydrogenase deficiency; Symptomatic hyperuricemia; Ileus; Colitis; Enterocolitis; Chronic hepatitis B virus disease...In protocol version 1.2 (April 8th, 2020): People in the control arm will receive a combination of vitamins and trace elements; people in the experimental arms will receive hydroxychloroquine, or favipiravir, or imatinib, or telmisartan...In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
- |||||||||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial) (Channel 19 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1608; P2 The 1st induction cycle consists of inotuzumab ozogamicin (InO) 0.8 mg/m2 on day1 and 0.5 mg/m2 on days 8 and 15 together with dexamethasone 10 mg/m2 (days 7-8, days 14-17) and 1 intrathecal injection of methotrexate (MTX), cytarabine (AraC) and dexamethasone (Dexa)...Patients achieving a complete remission are offered to receive 5 conventional consolidation therapies (3 x ID-MTX/asparaginase; 2 x ID-AraC) and one reinduction therapy (idarubicine/AraC/cycloph./Dexa) in combination with rituximab (for CD20+ ALL), followed by a maintenance therapy with 6-mercaptopurine/MTX... Replacement of conventional induction chemotherapy by InO is feasible, results in promising remission rates, and may reduce the risk of early morbidity and lethality, particular in older patients with acute B lymphoblastic leukemia.
|